Adam R. Craig

CIK: 0001339498

Transaction Breakdown

Open Market Buys (P)2 (33.3%)

High conviction signal

Open Market Sales (S)1 (16.7%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

XFOR

X4 Pharmaceuticals, Inc

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (6 total)

XFOR
X4 Pharmaceuticals, Inc
Oct 16, 2026
Purchase(P)
Direct
4.6K shares at avg. $2.58$12K
XFOR
X4 Pharmaceuticals, Inc
Aug 12, 2026
Sale(S)
Direct
47.4K shares at avg. $4.44$211K
XFOR
X4 Pharmaceuticals, Inc
Oct 29, 2025
Award(A)
Stock Option (right to buy)
Direct
2.3M shares-
XFOR
X4 Pharmaceuticals, Inc
Oct 23, 2025
Purchase(P)
Direct
86.2K shares at avg. $2.90$250K
XFOR
X4 Pharmaceuticals, Inc
Aug 14, 2025
Award(A)
Direct
289.9K shares-
XFOR
X4 Pharmaceuticals, Inc
Aug 12, 2025
Award(A)
Stock Option (right to buy)
Direct
1.6M shares-

		Type	Shares	Price		Ownership
Oct 16, 2026	XFOR X4 Pharmaceuticals, Inc	Purchase(P)	4,600	$2.58	$11,884	Direct
Aug 12, 2026	XFOR X4 Pharmaceuticals, Inc	Sale(S)	47,436	$4.44	$210,829	Direct
Oct 29, 2025	XFOR X4 Pharmaceuticals, Inc	Award(A) Stock Option (right to buy)	2,329,154	-	-	Direct
Oct 23, 2025	XFOR X4 Pharmaceuticals, Inc	Purchase(P)	86,206	$2.90	$249,997	Direct
Aug 14, 2025	XFOR X4 Pharmaceuticals, Inc	Award(A)	289,881	-	-	Direct
Aug 12, 2025	XFOR X4 Pharmaceuticals, Inc	Award(A) Stock Option (right to buy)	1,609,873	-	-	Direct

1-6 of 6 transactions

About Craig Adam R

Craig Adam R (SEC CIK 0001339498) files insider reports with the SEC as Executive Chairman of X4 Pharmaceuticals, Inc (XFOR).

Signal8 holds 6 ownership filings by Craig Adam R (1 Form 3, 5 Form 4), filed between Aug 14, 2025 and Oct 19, 2026. Those filings report 6 transactions, from Aug 12, 2025 to Oct 16, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Craig Adam R's filings is in BOSTON, MA.

Recent filings by Craig Adam R

Oct 16, 2026: Open-market purchase of XFOR shares (Form 4, code P).
Aug 12, 2026: Open-market sale of XFOR shares (Form 4, code S).
Oct 29, 2025: Grant or award of XFOR derivative securities (Form 4, code A).
Oct 23, 2025: Open-market purchase of XFOR shares (Form 4, code P).
Aug 14, 2025: Grant or award of XFOR shares (Form 4, code A).

Other insiders filing for X4 Pharmaceuticals, Inc (XFOR)

KIRSKE DAVID, Chief Financial Officer
Volpone John, President
Gold Kelly, Director
Bridger Gary, Director
de Craecker Francoise, Director
WYZGA MICHAEL S, Director

How to read Form 4 transaction codes